BioCentury
ARTICLE | Clinical News

NFC-1: Phase II/III started

June 27, 2016 7:00 AM UTC

Medgenics began the double-blind, placebo-controlled, U.S. Phase II/III SAGA trial to evaluate 100, 200 and 400 mg oral NFC-1 twice daily for 6 weeks in 90 patients ages 12-17. In 1H17, Medgenics plan...